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OSCA: a tool for omic-data-based complex
trait analysis
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Naomi R. Wray1,4, Peter M. Visscher1,4, Allan F. McRae1 and Jian Yang1,4,5*
Abstract
The rapid increase of omic data has greatly facilitated the investigation of associations between omic profiles such
as DNA methylation (DNAm) and complex traits in large cohorts. Here, we propose a mixed-linear-model-based
method called MOMENT that tests for association between a DNAm probe and trait with all other distal probes
fitted in multiple random-effect components to account for unobserved confounders. We demonstrate by
simulations that MOMENT shows a lower false positive rate and more robustness than existing methods. MOMENT
has been implemented in a versatile software package called OSCA together with a number of other
implementations for omic-data-based analyses.
Introduction
The rapid proliferation of genetic and omic data in large
cohort-based samples in the past decade has greatly ad-
vanced our understanding of the genetic architecture of
omic profiles and the molecular mechanisms underpin-
ning the genetic variation of human complex traits [1–3].
These advances include the identification of a large num-
ber of genetic variants associated with gene expression [4,
5], DNA methylation [6, 7], histone modification [8, 9],
and protein abundance [10, 11]; the discovery of omic
measures associated with complex traits [12, 13]; the im-
proved accuracy in predicting a trait using omic data [14,
15]; and the prioritization of gene targets for complex
traits by integrating genetic and omic data in large sam-
ples [3, 13, 16–18]. These advances have also led to the
development of software tools, focusing on a range of dif-
ferent aspects of omic data analysis. Therefore, a software
tool that implements reliable and robust statistical
methods for comprehensive analysis of omic data with
high-performance computing efficiency is required.
A well-recognized challenge in omic-data-based analysis
is to control for false positive rate (FPR) in the presence of
confounding factors, as failing to model the confounders
may lead to spurious associations [19–21] and/or a loss of
statistical power [22]. While some confounders (e.g., age
and sex) are known and available in most data so that
their effects can be accounted for by fitting them as covar-
iates in linear models, others are either uncharacterized or
difficult to measure. For example, in DNA methylation
(DNAm) data from whole blood, cell type compositions
(CTCs) are evident confounders in a methylome-wide as-
sociation study (MWAS; also known as an epigenome-
wide association study or EWAS) [21, 23, 24] although
CTCs may be useful for the prediction of some pheno-
types. CTCs tend to be correlated with the DNAm at CpG
sites that are differentially methylated in different cell
types (namely differentially methylated sites) and have
been shown to be associated with age and multiple traits
and diseases [19, 21, 25, 26]. MWAS analysis without ac-
counting for CTCs could give rise to biased test statistics
unless neither CTCs nor DNAm sites are associated with
the trait in question. Although it is possible to measure
CTCs directly or predict them by reference-based predic-
tion methods [27, 28], reference-free methods that are
able to correct for confounding effects without the need
of characterizing all the confounders have broader appli-
cations [22, 29–32]. Moreover, the predicted CTCs often
only explain a certain proportion of variation in CTCs
resulting in biased test statistics due to the uncaptured
variation in CTCs. Existing reference-free methods are
mainly based on the strategy of fitting a number of
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covariates (estimated from factor analysis or similar ap-
proaches with or without reference [22, 29, 31, 32]) in a
fixed-effect model or a set of selected DNAm probes in a
mixed linear model (MLM) [30]. However, uncharacter-
ized confounders with small to moderate effects and
numerous correlations between distal DNAm probes (e.g.,
those on different chromosomes) induced by the con-
founders may not be well captured by either a fixed num-
ber of principal features or a subset of selected probes.
In this study, we proposed a reference-free method
(called MOA: MLM-based omic association) that fits
all probes as random effects in an MLM-based associ-
ation analysis to account for the confounding effects,
including the correlations among distal probes
induced by the confounding. We then extended the
method to stratify the probes into multiple random-
effect components (called MOMENT: multi-
component MLM-based omic association excluding
the target) to model a scenario where some probes
are much more strongly associated with the pheno-
type than others. We evaluated the performance of
MOA and MOMENT by extensive simulations and
demonstrated their reliability and robustness in
comparison with existing methods. We have imple-
mented MOA and MOMENT together with a com-
prehensive set of other methods for omic data
analysis in an easy-to-use and computationally effi-
cient software package, OSCA (omic-data-based com-
plex trait analysis).
Results
Overview of the OSCA software
OSCA comprises four main modules: (1) data manage-
ment for which we designed a binary format to efficiently
store and manage omic data; (2) linear-regression- and
MLM-based methods (including the methods proposed in
this study) to test for associations between omic measures
and complex traits; (3) methods to estimate the propor-
tion of variance in a complex trait captured by all the
measures of one or multiple omic profiles (e.g., all SNPs
and DNAm probes) and to predict the trait phenotype in
a new sample based on the joint effects of all omic mea-
sures estimated in a discovery sample; and (4) an efficient
implementation of the methods to identify genetic vari-
ants associated with an omic profile, e.g., DNA methyla-
tion quantitative trait loci (mQTL) analysis. We will
describe the methods based on DNAm data, but the
methods and software tool are in principle applicable to
other types of omic data including gene expression, his-
tone modification, and protein abundance. The computer
code of OSCA is written in C++ programming language
and supports multi-threading based on OpenMP for high-
performance computing. The compiled binary files are
freely available at http://cnsgenomics.com/software/osca/.
MLM-based omic association analysis methods
One of the primary applications of OSCA is to test for as-
sociations between omic measures (e.g., DNAm probes)
and a complex trait (e.g., body mass index (BMI)) correct-
ing for confounding effects. In an MWAS, the test statis-
tics of null probes can be inflated because of the
associations of probes with confounders that are corre-
lated with the phenotype. Note that, even if the con-
founders are not directly associated with the phenotype,
the presence of confounders (e.g., CTCs or experimental
batches) can cause correlations between the trait-
associated probes and the null probes in distal genomic
regions or even on different chromosomes, giving rise to
inflated test statistics of the null probes (see the simulation
results below). Existing methods that fit a number of co-
variates computed from dimension reduction approaches
in a fixed-effect model [22, 31, 32] or a set of selected
DNAm probes in an MLM [30] may not be sufficient to
correct for confounding effects widely spread among a
large number of probes or correlations between distal
probes induced by the confounding. We propose two
MLM-based approaches (MOA and MOMENT) that in-
clude all the (distal) probes as random effects in the model
to account for the effects of the confounders on the trait
and probes as well as the correlations among distal
probes. We show by simulations (see below) that both
MOA and MOMENT are more robust than existing
methods in controlling for false positive rate (FPR) and
family-wise error rate (FWER) in MWAS (see below).
Here, we start with a general MLM that fits all probes
as random effects, i.e.,
y ¼ CβþWuþ e ð1Þ
where y is an n × 1 vector of phenotype values with n
being the sample size, C is an n × p matrix for covariates
(e.g., age and sex) with p being the number of covariates,
β is a p × 1 vector of the effects of covariates on the
phenotype, W is an n ×m matrix of standardized DNAm
measures of all m probes, u is an m × 1 vector of the
joint effects of all probes on the phenotype, and e is an
n × 1 vector of residuals. In this model, β are fixed ef-
fects whereas u and e are random effects with uNð0; I
σ2uÞ and eNð0; Iσ2eÞ: The variance-covariance matrix
for y is varðyÞ ¼ V ¼ WW0σ2u þ Iσ2e . This equation can
be re-written as.
V ¼ Aσ2o þ Iσ2e withA ¼ WW0=m andσ2o ¼ mσ2u ð2Þ
where A is defined as the omic-data-based relationship
matrix (ORM) (“Methods” section) and σ2o is the amount
of phenotypic variance captured by all probes. The vari-
ance components (σ2o and σ
2
e ) in such an MLM can be
estimated by REML algorithms [33]. Analogous to the
method for estimating SNP-based heritability [34, 35],
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the proportion of variance in the phenotype captured by
all the probes can be defined as ρ2 ¼ σ2o=ðσ2o þ σ2eÞ . We
name this variance-estimation method OREML follow-
ing the nomenclature of GREML [34]. The estimated
joint probe effects (u^) from this model by a random-effect
estimation approach (e.g., BLUP [36]) can be used to pre-
dict the phenotypes of individuals in a new sample based
on omic data, i.e., y^new¼Wnewu^. We call this OBLUP.
Model [1] can be extended to test for association be-
tween a probe i and the trait, i.e.,
y ¼ wibi þ CβþWuþ ewithV ¼WW0σ2u þ Iσ2e ð3Þ
In comparison to model [1], this model has two add-
itional terms, wi (an n × 1 vector of standardized DNAm
measures of a probe i, i.e., the target probe) and bi (the
effect of probe i on the phenotype; fixed effect). The
probe effect bi (together with the covariates’ effects) can
be estimated by the generalized least squares (GLS) ap-
proach, i.e., ½b^i β^0 ¼ ðX0V−1XÞ−1X0V−1y and var½b^i β^T
¼ ðX0V−1XÞ−1 with X = [wi C]. The sampling variance
(standard error (SE) squared) of b^i is the first diagonal
element of var½b^i β^T . The null hypothesis (H0 : bi = 0)
can be tested by a two-sided t test (or approximately
chi-squared test if sample size is large) given b^i and its
SE. We call this method MOA. Applying this method to
test each of the probes across the genome is extremely
computationally expensive because the variance compo-
nents σ2u and σ
2
e need to be estimated repeatedly for each
probe by REML that requires the computation of V−1
(computational complexity of O(n3)) multiple times in
an iterative process. To speed up the computation, we
use a two-step approach as in [37] to compute V−1, with
the first step to perform an eigendecomposition of WW
′ and the second step to compute V−1 based on the ei-
genvalues and eigenvectors. Since the eigendecomposi-
tion only needs to be done once for the whole genome
scan, this two-step approach reduces the complexity of
computing V−1 by orders of magnitude when testing
each specific probe. Moreover, as the proportion of
phenotypic variance attributable to a single probe is
often very small, we can further speed up the computa-
tion by an approximate approach (similar to the approxi-
mate MLM-based GWAS methods [38, 39]) that only
requires to compute V−1 once, assuming that the esti-
mates of σ2u and σ
2
e under the null (i.e., bi = 0) are ap-
proximately equal to those under the alternative (i.e.,
bi ≠ 0). Both the approximate and exact MOA ap-
proaches have been implemented in OSCA.
There are two properties of the MOA method worthy
of consideration. First, the target probe is fitted twice in
the MOA model, once as a fixed effect (bi) and again as
a random effect (the ith element of u), resulting in a loss
of power to detect bi (a recognized issue in MLM-based
association analysis with SNP data [39, 40]). This
problem can be solved by leaving out probes in close
physical proximity of the target probe (including the tar-
get) from the random-effect term because DNAm status
of CpG sites in close physical proximity is likely to be
regulated by the same mechanism and therefore tends to
be highly correlated. This strategy has been used previ-
ously in both GWAS (genome-wide association study)
[39, 40] and MWAS [30]. In practice, we exclude the
probes < 50 kb from the target probe. Note that the dis-
tance parameter may differ for other types of omic data
(e.g., a window size of 100 kbp is recommended for gene
expression data; see below for details). Second, MOA as-
sumes a single distribution to all the probe effects in the
random-effect term, which may not be well fitted to data
if some probes have much stronger associations with the
trait than other probes. For example, if CTCs are associ-
ated with the phenotype, then all the probes that are
highly differentially methylated in different cell types
[41–43] may present a very different distribution of ef-
fects from the other probes. One solution to this issue is
to stratify the probes into multiple groups by the associ-
ation test statistics (from linear regression) and fit them
as separate random-effect terms in the model. We ex-
tended the MOA method with the two modifications
mentioned above and named it as MOMENT (multi-
component MLM-based omic association excluding the
target). The MOMENT model can be written as
y ¼ wibi þ Cβþ
X
j







u j þ Iσ2e
ð4Þ
where Wj is an n ×mj matrix of standardized DNAm
measures of the probes in the jth group with mj being
the number of probes in the group (excluding probes
within 50Kb of the target probe). In practice, the probes
are split into two groups by association p values from a
linear regression model (i.e., y =wibi +Cβ + e) at a
methylome-wide significant threshold (all the
methylome-wide significant probes in the first group
and the other probes in the second group). The GLS
method described in model [3] can be used to estimate
bi and its SE for hypothesis testing. Like the exact MOA
method, MOMENT is also computationally intensive
when applied in a methylome-wide analysis. We can use
a similar approximation approach as described above
(i.e., using the variance components estimated under the
null to compute b^i and SE) to reduce the computing
cost. The variance components are re-estimated when
one or more probes are excluded from the first group in
case that the proportion of phenotypic variance captured
by some of the probes in the first group are large.
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Simulation analysis
To quantify the false positive rate (or family-wise error
rate) and statistical power of MOMENT (implemented in
OSCA), we performed simulations based on DNAm and
CTC [44] measures on samples from the Lothian Birth
Cohorts (LBC) in three scenarios (Additional file 1: Note
S1). We simulated a phenotype (1) with effects from a set
of “causal probes” (randomly selected from all probes on
the odd chromosomes) but no direct effects from the
CTCs, (2) with small to large effects from CTCs but no ef-
fects from the probes, and (3) with effects from both the
causal probes and CTCs (Additional file 1: Note S1). Note
that we only sampled the causal probes from the odd
chromosomes in scenarios 1 and 3, leaving the probes on
the even chromosomes to quantify false positive rate
under the null, and that the DNAm measures were ad-
justed for age, sex, experimental batches, and smoking sta-
tus. Results from our models were compared to 6
different methods including (1) Unadj: linear regression
without adjustment; (2) CTCadj: linear regression with
CTCs fitted as covariates; (3) SVA: linear regression with
the SVA surrogate variables fitted as covariates [22]; (4)
LFMM2-ridge: a latent factor mixed model (LFMM) using
ridge algorithm for confounder estimation [32]; (5)
LFMM2-lasso: an LFMM using lasso algorithm for con-
founder estimation [32]; (6) ReFACTor: linear regression
with the first 5 sparse principal components (PCs) from
ReFACTor fitted as covariates [31]; (7) 5PCs: linear re-
gression with the first 5 PCs, computed from a principal
component analysis (PCA), fitted as covariates; and (8)
FaST-LMM-EWASher: a set of selected probes fitted as
random effect in an MLM [30]. For completeness of the
analysis, we also included MOA (implemented in OSCA)
in the comparison. We validated using a subset of data
generated from simulation scenario 1 that the test
statistics from the approximate MOA/MOMENT ap-
proach were extremely highly correlated with those from
the corresponding exact approach (Pearson correlation >
0.999 for causal probes and > 0.998 for null probes;
Additional file 1: Figure S1). Hence, for the ease of
computation, we used the approximate MOA/MOMENT
approach in all the subsequent analyses.
In simulation scenario 1, although there were no direct
effects of the CTCs on the phenotype, the test statistics
from Unadj at the null probes were inflated (Fig. 1a and
Additional file 1: Table S1) because the null and causal
probes—albeit on different sets of chromosomes—are cor-
related through their correlations with systematic biases
such as CTCs. The mean genomic inflation factor (λ) [45]
of the null probes (on the even chromosomes) from 100
simulation replicates was 7.67 for Unadj (Additional file 1:
Table S1), where λ is defined as the median of χ2 test sta-
tistics of the null probes divided by its expected value.
CTCadj reduced but not completely removed the inflation
in test statistics of the null probes (Fig. 1a and Add-
itional file 1: Table S1), suggesting that the inflation was
caused by correlations between the causal and null probes
because of the confounding effects of both CTCs and
other unobserved confounders. While all the other
methods were much less inflated compared to Unadj,
MOMENT and MOA showed the least inflation with a
mean λ value close to 1. It is slightly surprising to observe
that the family-wise error rates (FWERs) of all the
methods except MOA and MOMENT were highly in-
flated (FWERs > 0.6) (Additional file 1: Figure S2a and
Additional file 1: Table S1) despite the relatively small gen-
omic inflation at the null probes for most of the methods
(Fig. 1a). Here, FWER is defined as the proportion of
simulation replicates with at least one null probe at
MWAS p value < 0.05/m with m being the number of null
probes, which can be interpreted as the probability of ob-
serving one or more false positives at a methylome-wide
significance level in a single experiment. There was no in-
flation in FWER for MOMENT, and a marginal inflation
for MOA (Additional file 1: Figure S2a and Add-
itional file 1: Table S1), showing the effectiveness of using
all (distal) probes to account for the probe correlations.
We also quantified the FPR, defined as the proportion of
null probes with p values < 0.05 in each simulation repli-
cate. The differences in FPR among the methods showed
a similar pattern to the differences in genomic inflation
factor (Additional file 1: Figure S2b and Additional file 1:
Table S1). We then compared power among the methods.
Since the test statistics of many approaches were highly
inflated, it is not very meaningful to compare power with-
out accounting for the inflation. We therefore used the
area under the ROC curve (AUC) to compare power of
the methods given the same level of FPR. Apart from
Unadj and CTC, the AUCs of all the methods were on
similar levels (Fig. 1b). The conclusions held in additional
simulations varying the number of causal probes and the
proportion of phenotypic variance captured by the causal
probes (Additional file 1: Figure S3 and S4) despite that
the inflation in FWER for the existing methods appeared
to increase with the increase of the proportion of variance
captured per causal probe. Additionally, we applied
BACON, a summary-data-based method that seeks to re-
move genomic inflation taking the true positives into con-
sideration, to the test statistics of all probes produced by
the methods tested above. We showed that the inflation in
test statistics of the null probes for Unadj was substantially
reduced but not completely removed by the BACON ad-
justment and that the test statistics from MOA and MO-
MENT remained almost unchanged after the BACON
adjustment (Additional file 1: Figure S5).
In simulation scenario 2 where there is no direct probe-
trait association, all the probes are null and their χ2 test sta-
tistics are expected to follow a χ2 distribution with 1 degree
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of freedom if the effects of CTCs have been well accounted
for. The results showed that the λ value was close to 1 for
all the methods except Unadj and FaST-LMM-EWASher
(Fig. 2a). It seems that, for some of the methods (e.g., 5PCs
and ReFACTor), the λ value slightly increased with the in-
crease of the proportion of variance explained by the CTCs
(R2CTCs) (Fig. 2a). The FPRs of the methods were highly con-
sistent with the genomic inflation factors (Additional file 1:
Figure S6). Nevertheless, a non-inflated median test statistic
does not necessarily mean that the FWER has been well
controlled for. In fact, most methods showed inflated
FWER in this simulation scenario, and the FWERs of all
the methods increased with increasing R2CTCs (Fig. 2b). The
FWERs of 5PCs, ReFACTor, LFMM2-ridge, and LFMM2-
lasso were close to the expected value (i.e., 0.05) when
R2CTCs ¼ 0:005 and increased to a level between 0.15 and
0.2 when R2CTCs ¼ 0:05 (Fig. 2b). The relationship between
FWER and R2CTCs was relatively flat for SVA with its FWER
varying from 0.05 to 0.1 when R2CTCs increased from 0.005
to 0.05. Although FaST-LMM-EWASher showed the most
deflated test statistics among all the methods (Fig. 2a), its
FWER was substantially higher than all the other methods
except Unadj (Fig. 2b), likely due to its feature selection
strategy (Additional file 1: Note S2). MOA and MOMENT
performed similarly in this simulation scenario and showed
the lowest inflation in FWER among all the methods with
their FWER being lower than 0.05 when R2CTCs = 0.005 and
increased to about 0.1 when R2CTCs = 0.05 (Fig. 2b). In
addition, we performed a linear regression analysis with the
known CTCs fitted as covariates; as expected, the FWER
was close to 0.05 irrespective of the level of R2CTCs (see
below for the analysis with predicted CTCs).
We also compared the methods under the circum-
stance (simulation scenario 3) where there were associa-
tions between the phenotype and CTCs (R2CTCs ¼ 0:05)
and the null probes were correlated with distal causal
probes because both of them were correlated with CTCs
(Additional file 1: Note S1). The results were similar to
those above (Fig. 1 and Additional file 1: Figure S2).
That is, the FWER of MOMENT was close to the ex-
pected value, demonstrating the reliability and robust-
ness of the method. The FWER of MOA is slightly
higher than that of MOMENT but much lower than
those of the other methods which showed strong infla-
tion in FWER and/or FPR due to the correlations be-
tween causal and null probes (Additional file 1: Figure
S7a, S7c, and S7d, and Additional file 1: Table S2). All
the methods showed similar levels of AUC except for
Unadj and CTCadj (Additional file 1: Figure S7b). The
conclusions held with different sample sizes (Add-
itional file 1: Figure S8 and S9) or different numbers of
causal probes with smaller or larger variance explained
per causal probe (Additional file 1: Figure S10 and S11).
The conclusions also held if we simulated confounding
Fig. 1 Power and false positive rate for the MWAS methods in simulation scenario 1. The phenotypes were simulated based on the effects from
100 causal probes but no direct effects from the CTCs. a Mean genomic inflation factor from a method across 100 simulation replicates with an
error bar representing ± SE of the mean. The dashed line at 1 shows the expected value if there is no inflation. b Box plot of AUCs for each
method from 100 simulation replicates
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effects on experimental batches in lieu of CTCs (Add-
itional file 1: Figure S12 and S13). We further demon-
strated that the result from MOA/MOMENT analysis of
the whole sample was consistent with that from a meta-
analysis of summary statistics from MOA/MOMENT
analyses in two halves of the sample (Additional file 1:
Figure S14) and that the methods were applicable to
case-control phenotypes (Additional file 1: Figure S15
and S16).
To explore the applicability of the proposed methods
to other types of omic data, we tested the methods by
simulation based on a real gene expression data set (19,
648 gene expression probes on 1219 Mexican American
individuals) from the San Antonio Family Heart Study
(SAFHS) [46–48] (“Methods” section) under simulation
scenario 1 (i.e., quantitative phenotypes simulated based
on the expression levels of 100 randomly selected causal
probes; Additional file 1: Note S1). The result showed
that both MOMENT and MOA performed similarly (in
comparison to the other methods) as in the simulations
based on DNAm data (Additional file 1: Figure S17).
We further compared the computational complexity
among the MWAS methods tested in this study and
quantified their runtime and memory usage of the
methods using simulated and real phenotypes in the
LBC (Additional file 1: Table S3). We found that MOA
and MOMENT showed the lowest memory usage among
all the methods. The approximate MOA approach was
the second fastest approach (only slightly slower than
LFMM2-ridge), and the approximate MOMENT
approach was slower than LFMM2-ridge, approximate
MOA, and ReFACTor but much faster than SVA,
LFMM2-lasso, and EWASher.
An application of MOMENT to real data
We applied MOMENT and the other methods to four
real quantitative traits in the LBC cohorts. These traits,
including BMI, height, lung function (measured in the
highest score of forced expiratory volume in 1 s), and
walking speed (measured in the time taken to walk 6 m),
were standardized and corrected for age in each gender
group within each sub-cohort (LBC1936 or LBC1921)
(“Methods” section). The standardized phenotypes were
further processed by a rank-based inverse-normal trans-
formation. The DNAm probes were adjusted for age,
sex, and experimental batches. We did not adjust the
probes for CTCs or smoking status for the purpose of
testing methods (see below).
Consistent with the results from simulations, the test
statistics from MOA and MOMENT were not inflated
whereas all the other methods showed modest inflation
for all the traits (Fig. 3, Table 1, and Additional file 1:
Figure S18-S21). Three associations were identified by
multiple methods, including one for BMI (cg11202345,
detected by all methods), in line with a previous study
[49], and two for lung function (cg05575921 and
Fig. 2 Genomic inflation factor and family-wise error rate for the MWAS methods in simulation scenario 2 (effects from CTCs but no causal
probes). Shown on the horizontal axis are the R2CTCs values used to simulate the phenotype. a Each dot represents the mean λ value from 1000
simulation replicates given a specified R2CTCs value for a method with an error bar representing ± SE of the mean. b Each dot represents the
family-wise error rate, calculated as the proportion of simulation replicates with one or more null probes detected at a methylome-wide
significance level
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cg05951221, detected by all methods except MOMENT)
(Additional file 1: Table S4, Additional file 1: Figure S18
and S20). It should be noted that cg05575921 was re-
ported to be associated with smoking in a previous study
[50], indicating that the association between cg05575921
and lung function might be confounded by smoking
status. Moreover, MOA, LFMM2-ridge, LFMM2-lasso,
and ReFACTor consistently identified 12 additional
probes associated with lung function but most of the
probes have been linked to smoking in a previous study
[51]. Almost all the associations were not significant when
smoking status was fitted as a covariate in the models
(6.5% of variance in lung function associated with smok-
ing status, Additional file 1: Table S5 and Additional file 1:
Figure S22), suggesting that most (if not all) of the probe
associations with lung function identified by MOA,
LFMM2-ridge, LFMM2-lasso, and ReFACTor were owing
to the confounding of smoking. None of the smoking-
associated probes were methylome-wide significant for
lung function in the analysis using MOMENT
(Additional file 1: Figure S20), and the result remained the
same when smoking status was fitted as a covariate in
MOMENT (Additional file 1: Figure S22), again demon-
strating the capability of MOMENT in correcting for
Fig. 3 QQ plot of p values from MWAS analysis for 4 quantitative traits in the LBC data. The DNAm measures were adjusted for age, sex, and
batches. The phenotypes were stratified into groups by sex and cohort and were adjusted for age and standardized to z-scores by rank-based
inverse normal transformation in each group. The phenotypes are a BMI, b height, c lung function, and d walking speed
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unobserved confounding factors. This is further supported
by the finding from simulations that the effects of null
probes estimated from MOMENT were much less corre-
lated with the phenotype compared to those estimated
from MOA (Additional file 1: Figure S23).
It has been shown in previous GWASs that MLM-
based association analysis methods developed for quanti-
tative traits are applicable to case-control data [37–39,
52]. We have shown by simulation that both MOMENT
and MOA are applicable to case-control phenotypes re-
gardless whether cases are oversampled (Additional file 1:
Figure S15 and S16). To demonstrate the applicability of
the proposed methods to discrete phenotypes, we
analyzed smoking status (coded as 0, 1, or 2 for non-
smoker, former smoker, or current smoker) in the LBC
by MOA and MOMENT in comparison with existing
methods. All the methods detected a large number (at
least 112) of probes at a methylome-wide significance
level (p < 2.19e−7) except for MOMENT and EWASher
which only identified 4 and 2 probes, respectively, at the
methylome-wide significance level (Additional file 1: Fig-
ure S24). To validate the association signals other than
those identified by MOMENT, we fitted the 4 MO-
MENT probes as fixed covariates in MOA. None of the
additional associations remained methylome-wide
significant conditioning on the 4 MOMENT probes
(Additional file 1: Figure S25), suggesting that those add-
itional associations detected by MOA (and other
methods) were driven by their correlations with the 4
MOMENT signals. MOA failed in this scenario likely be-
cause the associations of the 4 MOMENT signals were
too strong to be fitted in a single normal distribution
with the other probes. This conclusion is further sup-
ported by the result that the accuracy of predicting/clas-
sifying smoking status in a cross-validation setting using
a large number of probes detected by linear regression
or MOA was even lower than that using a small number
of probes detected by MOMENT (Additional file 1:
Table S6). In addition, we recoded the smoking status
data to a binary phenotype (0 for non-smoker and 1 for
former or current smoker) and applied all the methods
to the recoded binary phenotype; the conclusions were
similar as above but it seemed that the analyses with the
binary phenotype were less powerful than those with the
categorical phenotype above (Additional file 1: Figure
S26). All these results show the applicability of MO-
MENT to discrete traits and again demonstrate the ro-
bustness and reliability of MOMENT in controlling for
false positive associations.
Estimating variance in a phenotype captured by all
probes by OREML
We have demonstrated the performance of the omic-data-
based association analysis methods in OSCA by simulation
and real data analysis. We then turned to evaluate the per-
formance of OREML in estimating the proportion of vari-
ance in a complex trait captured by all probes (ρ2) by
simulation in two scenarios (Additional file 1: Note S1).
The results showed that under either scenario, OREML re-
ported an unbiased estimate of ρ2 (Additional file 1: Table
S7). Here, the unbiasedness is defined as that the mean ρ2
estimate from 500 independent simulations is not signifi-
cantly different from the ρ2 parameter used for simulation.
There are two methods implemented in OSCA to compute
the ORM (“Methods” section). Our simulation results
showed that the estimates of ρ2 based on the two methods
were similar (Additional file 1: Table S7).
We also attempted to partition and estimate the pro-
portions of phenotypic variation captured by all SNPs
(i.e., h2SNP ) and all the DNAm probes respectively when
fitted jointly in a model. We first investigated the correl-
ation between genomic relationship matrix (GRM) and
methylomic relationship matrix (MRM) in the LBC data-
set. We found that the off-diagonal elements of the
GRM were almost independent of those of the MRM (r
= 0.0045; Additional file 1: Figure S27). From an OREML
analysis that fits both the GRM and MRM, we estimated
that all the DNAm probes captured 6.5% (SE = 0.038) of
the variance for BMI but the estimate for height was
nearly zero ( ρ^2 = − 0.005 and SE = 0.0086) (Add-
itional file 1: Table S8). These results are in line with the
finding from a previous study that the accuracy of gen-
etic risk prediction can be improved by incorporating
DNAm data for BMI but not height [14].
Discussion
In this study, we developed a versatile software tool—
OSCA—to manage omic data generated from high-
throughput experiments in large cohorts and to facilitate
the analyses of complex traits using omic data
(Additional file 1: Note S4). The primary applications of
OSCA are to identify omic measures associated with a
Table 1 Genomic inflation factors reported by different MWAS
methods for the 4 traits in the Lothian Birth Cohorts
BMI Height Lung function Walking speed
Unadjusted 1.68 1.30 0.98 1.28
5PCs 1.11 0.96 1.06 1.04
SVA 1.04 0.95 1.06 1.01
LFMM2-ridge 1.09 1.00 1.10 1.04
LFMM2-lasso 1.08 0.99 1.09 1.03
ReFACTor 1.13 0.97 1.09 1.02
EWASher 1.11 0.96 1.09 0.96
MOA 0.99 1.02 0.97 0.99
MOMENT 1.00 1.02 0.98 1.00
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complex trait accounting for unobserved confounding fac-
tors (MOMENT) and to estimate the proportion of pheno-
typic variation captured by all measures of one or multiple
omic profiles (OREML). A by-product of the OREML ap-
plication is to estimate the joint effects of all measures of
one or multiple omic profiles (i.e., OBLUP analysis) to pre-
dict the phenotype in a new sample. This has been shown
to be a powerful and robust approach in age prediction
using gene expression or DNAm data [53, 54]. We have
also provided computationally efficient implementations in
OSCA to manage large-scale omic data and to perform
omic-data-based quantitative trait locus (xQTL) analysis
and meta-analysis of xQTL summary data. OSCA is an on-
going software development project so that any further
methods or functions related to omic-data-based analysis
can be included in the software package in the future.
We showed, by simulation, a surprisingly high error rate
for all the existing MWAS/EWAS methods, mainly owing
to the correlations between distal probes induced by CTCs
(and/or other systematic confounders) in DNAm data
(Fig. 1). These correlations are widespread at a large num-
ber of probes across the methylome (as demonstrated by
the proportion of null probes with PMWAS < 0.05 in simula-
tion scenario 1; Additional file 1: Figure S28) and thus are
not adequately accounted for by a fixed number of princi-
pal features computed from the data (e.g., 5PCs, ReFACTor,
LFMM2, and SVA) nor a set of selected probes (e.g., FaST-
LMM-EWASher). This conclusion is likely to be applicable
to other types of omic data if the measures in distal gen-
omic regions are correlated due to unmeasured confound-
ing factors such as systematic experimental biases or
unwanted biological variation, as suggested by our simula-
tions with gene expression data (Additional file 1: Figure
S17). This confounding effect can be corrected for by fitting
the target probe as a fixed effect and all the other (distal)
probes as random effects (i.e., the MOA or MOMENT
method). In addition, we tested the robustness of MO-
MENT to the change of window size used to exclude
probes in close physical proximity to the target probe in ei-
ther direction. We varied the window size from 100 kbp to
250 bp in the MOMENT analysis of data generated from
simulation scenario 1 (Additional file 1: Figure S29). We
found that the results remained almost unchanged when
the window sizes decreased from 100 to 25 kbp whereas
there were a substantial number of probes showing deflated
test statistics when the window size decreased to 500 bp or
250 bp (Additional file 1: Figure S29). These results justify
the use of 50 kbp as the default window size for MOMENT
when applied to DNAm data. We also quantified the decay
of correlation between a pair of gene expression probes as a
function of their physical distance (Additional file 1: Figure
S30), which suggests that 100 kbp is an appropriate MO-
MENT window size for gene expression data although the
results remained almost unchanged when the window size
was varied from 50 kbp to 1Mbp in the simulated data
(Additional file 1: Figure S31).
Our simulation also showed that, if CTCs or batches ex-
plain a large proportion of variation in the phenotype, the
FWERs of all the methods tended to be inflated (Add-
itional file 1: Figure S32 and S33) despite that the genomic
inflation factor is close to unity for most methods (Fig. 2).
We re-ran the simulation under a more extreme setting
with R2CTCs varying from 10 to 70%. In this case, the gen-
omic inflation factors of the fixed-effect models (i.e., SVA,
ReFACTor, LFMM2, and 5PCs) and the FWERs of all the
methods increased as R2CTCs increased (to a lesser extent for
FaST-LMM-EWASher), suggesting that there were a set of
probes strongly associated with CTCs (Additional file 1:
Figure S34). Note that even in this extreme case, MO-
MENT showed the lowest FWERs on average among all
the methods. It is also of note that the FWERs of FaST-
LMM-EWASher were relatively low in this scenario (Add-
itional file 1: Figure S32), opposite to its performance when
R2CTCs was low (Fig. 2), possibly due to its variable selection
strategy (Additional file 1: Note S2). The inflation in FWER
was only slightly alleviated by fitting the predicted CTCs as
covariates (Additional file 1: Figures S35 and S36). The
results also suggest that it may be worth fitting measured
CTCs as fixed-effect covariates in MLM-based association
analyses such as MOA and MOMENT in practice although
this approach is likely to be conservative as indicated by the
deflated λ and FWER (Additional file 1: Figure S37). These
conclusions are likely to be applicable to other confounding
factors such as smoking status, as demonstrated in the ana-
lysis of lung function data in the LBC (Additional file 1: Fig-
ure S22). Our results also caution the interpretation of
associations identified from MWAS for traits that are
highly correlated with CTCs and/or other biological con-
founders. In addition, although our simulation shows that
both MOMENT and MOA are applicable to case-control
phenotypes (Additional file 1: Figures S15 and S16), direct
application of linear model approaches to 0/1 traits is not
ideal. If the underlying model is causal (i.e., omic measures
have causal effects on the trait), a more appropriate analysis
is to use a link function (e.g., a probit or logit model) that
connects the 0/1 phenotype to a latent continuous trait, as
in the methods recently developed for the analysis of case-
control data in GWAS [55–58]. Since OSCA is an ongoing
software development project, the non-linear link functions
can be incorporated in the MOMENT/MOA framework in
the future.
In conclusion, we showed by simulation the inflation in
test statistics of the existing MWAS methods because of
the ubiquitous correlations between distal probes caused by
confounding factors, and developed two new MWAS
methods (MOA and MOMENT) to correct for the infla-
tion. We demonstrated the reliability and robustness of
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MOMENT by simulations in a number of scenarios and
real data analyses. We recommend the use of MOMENT
in practice because of its robustness in the presence of un-
observed confounders despite that it is slightly less powerful
than MOA. We implemented both MOA and MOMENT
in a computationally efficient and easy-to-use software tool
OSCA together with many other functions for omic-data-
based analyses (Additional file 1: Figure S38).
Methods
Omic-data-based relationship matrix (ORM)
We have described in Eqs. (1, 2) the OREML model to es-
timate the proportion of variance in a phenotype captured
by the DNAm probes all together. In Eq. (1), i.e., y =Cβ +
Wu + e, we define W as a matrix of standardized DNAm
measures of all probes, and in Eq. (2), we define the ORM
as A =WW ′ /m. Therefore, the omic relationship be-
tween individual j and k (the jkth element of A) can be
computed as Ajk ¼ 1m
X
i
ðxij−μiÞðxik−μiÞ=σ2i , where xij is
the unstandardized DNAm level of probe i in individual j,
μi and σ2i are the mean and variance of the ith probe over
all the individuals respectively, and m is the number of
probes. This model implicitly assumes that the probes of
smaller variance in DNAm level (unstandardized) tend to
have larger effects on the phenotype (strictly speaking,
stronger associations with the phenotype) and that there
is no relationship between the proportion of trait variance
captured by a probe and the variance of the probe. We
also provide in OSCA an alternative method to compute






σ2i . If we use
this definition of ORM in the OREML analysis, we impli-
citly assume that there is no relationship between the
probe effect on the trait and the variance of the probe but
the proportion of trait variance associated with a probe in-
creases as the variance of the probe increases. We showed
by simulation and real data analysis that the difference be-
tween OREML results using the two methods was very
small (Additional file 1: Tables S7 and S8).
OREML: estimating the proportion of trait variance
captured by all DNAm probes
We have shown in Eqs. (1, 2) an OREML model with
one random-effect component to estimate the propor-
tion of trait variance captured by all DNAm probes. The
model is flexible, which can be extended to partition the
trait variance into components associated with different
sets of probes (e.g., a model with 22 components with
all the probes on each chromosome as a component). A
flexible OREML model can be written as.









where the definitions of all the parameters and vari-
ables are similar to those in Eqs. (1, 2). The variance
components can be estimated by REML [33], and the
proportion of the trait variance captured by the ith com-





The multi-component OREML model can be applied to
partition the trait variance into components associated with
multiple omic profiles. For example, if SNP genotype,
DNAm, and gene expression data are available for all the in-
dividuals in a cohort, a multi-component OREML model can
be used to estimate the proportion of trait variance captured
by all SNPs (i.e., the SNP-based heritability), the expression
levels of all genes, and the DNAm levels at all the CpG sites.
The model can be written as y=Cβ+Wgug+Wtut+Wmum
+ e with varðyÞ¼Agσ2g þ Atσ2t þ Amσ2m þ Iσ2e
whereWg,Wt, andWm are the matrices of standardized
SNP genotypes, gene expression measures, and DNAm
levels, respectively, with the corresponding effects ug, ut,
and um; Ag ¼WgW0g=mg is the genomic relationship
matrix (GRM) with mg being the number of SNPs, At
¼WtW0t=mt is the transcriptomic relationship matrix
(TRM) with mt being the number of transcripts, and Am
¼WmW0m=mm is the methylomic relationship matrix
(MRM) with mm being the number of DNAm probes.
Note that the model can be reduced by dropping any of
the variance components or expanded by including other
types of omic profiles (e.g., protein abundance).
Dataset
The LBC cohorts [59, 60] consisted of individuals born in
1921 (LBC1921) and 1936 (LBC1936), mostly living in Ed-
inburgh city and the surrounding Lothian region of
Scotland. Blood samples were collected with informed
consent. The LBC individuals underwent several waves of
SNP genotyping and DNAm measures. DNAm levels at
485,512 CpG sites across the genome were measured on
3191 whole blood samples from 3 waves using the Illu-
mina HumanMethylation450 BeadChip. Duplicates or
samples with an excessive proportion of low confidence
calls across all probes (> 5%) were removed. Probes with
an excessive proportion of low confidence calls across all
individuals (> 5%) or probes located in sex chromosomes
were excluded. In addition, probes encompassing SNPs
annotated in dbSNP131 using hg19 coordinates or identi-
fied as potentially cross-hybridized methylation probes by
a previous study [61] were also excluded. After these QC
steps, 3018 samples and 307,360 probes remained (Add-
itional file 1: Note S3). We included in the analysis only
the first wave (wave1) of the LBC data consisting of 436
individuals from LBC1921 (average age of 79 years) and
906 individuals from LBC1936 (average age of 70 years)
(Additional file 1: Table S9). We removed probes with al-
most invariable beta values across individuals (standard
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deviation < 0.02) and retained 1342 individuals and 228,
694 probes for analysis.
There were a number of covariates available in the
LBC data including age, sex, batches of the experiment
(i.e., plate and position of the sample on a chip), and
CTCs. The blood cell counts for different cell types, in-
cluding basophils, eosinophils, monocytes, lymphocytes,
and neutrophils, were quantified using an LH50 Beck-
man Coulter instrument on the same day of blood col-
lection. In addition to the covariates, there are a number
of traits measured on the LBC individuals including
height (measured without shoes), body mass index
(BMI), lung function (measured in the highest score of
forced expiratory volume in 1 s), walking speed (mea-
sured in the time taken to walk 6 m), and smoking status
(never smoked, ex-smoker, or current smoker) [62, 63].
The numbers of missing measurements are noted in
Additional file 1: Table S10. For each trait, we adjusted
the phenotype for age in each gender group of each co-
hort (LBC1921 or LBC1936) and standardized the resid-
uals by rank-based inverse normal transformation, which
removed the age effect and potential difference in mean
and variance between two gender groups or cohorts.
The LBC wave1 individuals were also genotyped by
Illumina 610-Quadv1 BeadChip. The QC process of the
SNP genotype data has been detailed elsewhere [14].
After excluding SNPs from sex chromosomes and SNPs
with low allelic frequency (MAF < 0.01), we retained 523,
062 genotyped SNPs for analysis.
We also used a set of gene expression data available at
EMBL-EBI (URLs) from the San Antonio Family Heart
Study (SAFHS). Sample recruitment, data generation,
and quality controls of the SAFHS data have been de-
tailed elsewhere [46–48]. We used the processed and
standardized gene expression data of 19,648 autosomal
probes on 1240 non-diseased Mexican American partici-
pants. Age, sex, and smoking status were available in the
data. We removed 21 samples with unknown smoking










The LBC data: https://www.ebi.ac.uk/ega/studies/
EGAS00001000910
The SAFHS data: https://www.ebi.ac.uk/arrayexpress/
experiments/E-TABM-305/
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